Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
Holding IMTX?
Track your performance easily
IMTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.46 - $13.77
Previous Close$8.32
Volume298.58K
Average Volume (3M)613.48K
Market Cap
$993.04M
Enterprise Value$562.52M
Total Cash (Recent Filing)€425.89M
Total Debt (Recent Filing)€15.40M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 19, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding103,110,000
10 Day Avg. Volume792,815
30 Day Avg. Volume613,484
Standard Deviation0.14
R-Squared0.11
Alpha-0.00614
Financial Highlights & Ratios
Price to Book (P/B)3.58
Price to Sales (P/S)13.38
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.92Price Target Upside109.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Immatics News
PremiumCompany Announcements
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
PremiumCompany Announcements
Immatics Sees Revenue Surge Despite R&D ExpensesBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessImpressive data was reported for IMA203, with a 62% overall response rate and a 92% disease control rate in a heavily pre-treated metastatic melanoma patient group.
Financial StabilityIMTX has a strong cash position with a financial runway into the second half of 2027.
Innovative TreatmentsTreatment with '402 led to 78% tumor shrinkage, with one confirmed partial response and stable diseases in melanoma and ovarian cancer.
Bears Say
Clinical Data TransparencyMany key details for the updated IMA203CD8 data were lacking in the abstract.
Efficacy DataEfficacy data on tumor types with larger commercial opportunities, such as ovarian, endometrial, and lung cancers, remain limited.
Safety ConcernsOne possible Grade 5 treatment-related adverse event of fatal sepsis was disclosed, highlighting a severe safety concern.
---
Ownership Overview
―
Insiders
11.00% Mutual Funds
47.53% Other Institutional Investors
41.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $7.46 and its highest was $13.77 in the past 12 months.
What is Immatics’s market cap?
Currently, no data Available
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Mar 19, 2025 which is in 106 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Nov 18, 2024. The company reported -$0.115 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.127.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -$0.31.
How many shares outstanding does Immatics have?
Immatics has 119,355,900 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.115 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went down -4.284%.
Which hedge fund is a major shareholder of Immatics?
Among the largest hedge funds holding Immatics’s share is Perceptive Advisors LLC. It holds Immatics’s shares valued at 92M.
---
Immatics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.92 (109.93% Upside)
$16.92 (109.93% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 760.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.65%
12-Months-Change
Fundamentals
Return on Equity
-17.48%
Trailing 12-Months
Asset Growth
39.10%
Trailing 12-Months
Company Description
Immatics
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
---
IMTX Stock 12 Month Forecast
Average Price Target
$16.92
▲(109.93% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Fate Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
-1.28%
reiterated a buy rating 12 days ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -1.28% per trade.
---